Almost one year ago, we published a series of articles, “Spotlight on mRNA”, which provided readers or our website with the scientific background, legal and commercial landscape, and regulatory considerations related to mRNA. Now, IP-focused magazine Managing IP listed the informative series in an IP Stars article focusing on the Moderna v Pfizer patent dispute related to the COVID-19 vaccines, citing it as a source for anyone interested in the topic.

The five part series was written by life science commercial IP expert Ellen Lambrix, life sciences regulatory advisors Julian Hitchcock and Hugo Kent-Egan, corporate law expert Nicholas Cross, and patent litigator Olivia Henry.

You can read all articles in the Spotlight on mRNA series here:

• A brief history of mRNA research
• Spotlight on mRNA – What is mRNA and what can it be used for?
• IP landscape
• Recent deal activity
• Regulation of mRNA vaccines and therapies